Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.33 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.33 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.33 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.31 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.31 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.31 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.31 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.31 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706392 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL19584438 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL15538337 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL16338157 | 0.83 | — | — | |
| SCHEMBL15038049 | 0.80 | — | — | |
| SCHEMBL20898998 | 0.80 | — | — | |
| SCHEMBL20898999 | 0.80 | — | — | |
| Trifluoroacetic Acid SCHEMBL3717511 | 0.78 | CPN1 (0.43) | CPN1CPB2SLC6A2SLC6A4GABRP | |
| SCHEMBL28019682 | 0.74 | — | — | |
| SCHEMBL19362521 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062804-A | Arenobufagin derivative, preparation method thereof, pharmaceutical composition and application | 安徽华润金蟾药业股份有限公司 | 2020-12-11 | — | — | CN | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | TEIJIN PHARMA LIMITED (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119451681-A | Medicament containing vitamin D derivative or pharmaceutically acceptable salt or solvate thereof for use in combination with immunomodulatory substance | 帝人制药株式会社 | 2025-02-14 | — | — | CN | disclosed |
| EP-4491185-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | Teijin Pharma Limited (JP) | 2025-01-15 | — | — | EP | disclosed |
| CN-119241414-A | Vitamin D derivatives having cyclic amine in side chain | 帝人制药株式会社 | 2025-01-03 | — | — | CN | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024032661-A1 | KIF18A INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| CN-111655699-A | Heterocyclyl substituted oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2020-09-11 | — | — | CN | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| WO-2019149659-A1 | HETEROCYCLYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2013067409-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | ALCON RESEARCH, LTD. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116219-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | ALCON RESEARCH, LTD. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | VDR, CYP24A1, AQP4 | SLC6A2 1060/4885SLC6A4 683/4885SLC6A3 305/4885 |
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | SLC6A2 4731/4885SLC6A4 4676/4885SLC6A3 4617/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | SLC6A2 4731/4885SLC6A4 4676/4885SLC6A3 4617/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | SLC6A2 4731/4885SLC6A4 4676/4885SLC6A3 4617/4885 |
| US-20130116219-A1 | ANTIMICROBIAL CARBOLINE COMPOUNDS | MAVS, OPA1, ZC3HAV1 | SLC6A2 3999/4885SLC6A4 3263/4885SLC6A3 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.